Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2016 - 2026)

Ani Pharmaceuticals' Long-Term Deferred Tax history spans 12 years, with the latest figure at $69.1 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 18.84% to $69.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.1 million, a 18.84% decrease, with the full-year FY2025 number at $69.1 million, down 18.84% from a year prior.
  • Long-Term Deferred Tax hit $69.1 million in Q4 2025 for Ani Pharmaceuticals, down from $71.4 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for ANIP hit a ceiling of $92.0 million in Q2 2025 and a floor of $52.0 million in Q1 2021.
  • Historically, Long-Term Deferred Tax has averaged $76.8 million across 5 years, with a median of $79.1 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 41.4% in 2022 and later dropped 19.82% in 2024.
  • Tracing ANIP's Long-Term Deferred Tax over 5 years: stood at $67.9 million in 2021, then grew by 19.76% to $81.4 million in 2022, then grew by 11.49% to $90.7 million in 2023, then decreased by 6.18% to $85.1 million in 2024, then dropped by 18.84% to $69.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for ANIP at $69.1 million in Q4 2025, $71.4 million in Q3 2025, and $92.0 million in Q2 2025.